Multiple immunosuppressive mechanisms cause resistance to anti-PD-L1/PD-1 therapy, such as the lack of cancer antigens, reduced infiltration of T cells in tumor tissue, and the production of immunosuppressive factors in the TME (Kim and Chen 2016). Here, CD274 is linked to cancer.